<DOC>
	<DOCNO>NCT00000855</DOCNO>
	<brief_summary>The purpose study examine safety tolerability ZDV give premature infant bear HIV-positive woman prevent HIV infection . ZDV use successfully prevent transmission HIV mother child pregnancy birth . However , ZDV give premature baby , best dose use yet determine .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Zidovudine ( ZDV ) Premature Infants Born HIV-Positive Women .</brief_title>
	<detailed_description>In preliminary group premature infant , receive q 6h dosing average trough concentration 7.3 uM ( 18 % ) . However , premature infant preliminary pharmacokinetic study long term follow-up ass toxicity . Due potential alter ZDV pharmacokinetics increase toxicity population , evaluation ZDV pharmacokinetics premature infant propose . Premature infant less equal 34 week gestational age birth begin ZDV clinical caregiver enter protocol within first 5 day life . Upon entry , ZDV administer every 12 hour intravenously orally . The study require 9 serum sample ZDV assay collect 30 day , additional clinical laboratory test collect 12 week , collection 3 spot urine sample , collection routine clinical data .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Your baby may eligible study he/she : Requires ZDV ( decide doctor ) HIVpositive . Is 15 day old born prematurely . Exclusion Criteria Your baby eligible study he/she : Is expect live 6 week severe illness . Is problem blood pressure urinate enough .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Days</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zidovudine</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>